The rules around peptides move fast. This page tracks FDA guidance, compounding policy, anti-doping status and notable research — refreshed every week.
Last updated: 2026-07-26
FDA
Compounded GLP-1 shortage exemptions continue to narrow
Following the resolution of the semaglutide and tirzepatide shortage designations, FDA has continued to tighten the conditions under which 503A and 503B facilities may compound GLP-1 analogs. Enforcement discretion that applied during the shortage period no longer covers essentially-copy compounding.
What it means: Research-use material remains a distinct category from compounded drug product. Verify that any supplier is selling clearly labeled laboratory research material with a batch certificate of analysis.
Research
Retatrutide phase 3 data continues to dominate metabolic research discussion
The triple agonist (GLP-1 / GIP / glucagon) remains the most-watched compound in metabolic literature, with published phase 2 results reporting substantially greater mean weight reduction than dual-agonist comparators over 48 weeks.
What it means: Retatrutide is still investigational and not approved. Interest in research-grade material has grown sharply; purity documentation is the differentiator.
Regulatory
BPC-157 remains on the FDA 503A bulks 'Category 2' list
FDA has kept BPC-157 in the category of substances that raise significant safety risks for compounding pending further evaluation, citing limited human pharmacokinetic data despite an extensive animal-model literature.
What it means: BPC-157 continues to be sold legitimately as a laboratory research chemical. It is not available as a compounded prescription product in the United States.
Regulatory
WADA prohibited list: growth hormone secretagogues stay in scope
The World Anti-Doping Agency's current list continues to prohibit GH secretagogues and GHRH analogs — including ipamorelin, CJC-1295 and tesamorelin — in and out of competition under section S2.
What it means: Any tested athlete should treat these compounds as prohibited. Recreational and research contexts are unaffected.
Industry
State-level oversight of peptide marketing increases
Several state attorneys general have issued guidance on the marketing of research chemicals to consumers, focusing on unsubstantiated therapeutic claims rather than the sale of research material itself.
What it means: Reputable suppliers avoid therapeutic claims entirely and publish third-party analytics. That's the standard we hold ourselves to.
Industry
Third-party testing becomes the default consumer expectation
Independent surveys of the research-peptide market continue to report wide purity variance across suppliers, with published HPLC and mass-spec certificates emerging as the primary trust signal buyers screen for.
What it means: Every Peptide Logix batch is tested in a USA third-party lab at 99%+ purity, with the certificate published openly.
Sourced the way the rules expect
Laboratory research material, 99%+ purity, third-party USA tested, COA published.